1. Home
  2. CNC vs KVUE Comparison

CNC vs KVUE Comparison

Compare CNC & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Centene Corporation

CNC

Centene Corporation

HOLD

Current Price

$67.42

Market Cap

32.1B

Sector

Health Care

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$19.82

Market Cap

32.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNC
KVUE
Founded
1984
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Specialty Chemicals
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
32.1B
32.9B
IPO Year
2001
2023

Fundamental Metrics

Financial Performance
Metric
CNC
KVUE
Price
$67.42
$19.82
Analyst Decision
Buy
Buy
Analyst Count
16
11
Target Price
$46.75
$19.45
AVG Volume (30 Days)
4.0M
19.0M
Earning Date
04-28-2026
05-07-2026
Dividend Yield
N/A
4.82%
EPS Growth
N/A
40.74
EPS
3.11
0.25
Revenue
$194,777,000,000.00
$15,124,000,000.00
Revenue This Year
$8.31
$4.85
Revenue Next Year
$1.05
$2.63
P/E Ratio
$21.80
$79.22
Revenue Growth
19.44
N/A
52 Week Low
$25.08
$14.02
52 Week High
$69.29
$22.87

Technical Indicators

Market Signals
Indicator
CNC
KVUE
Relative Strength Index (RSI) 65.88 75.51
Support Level $33.27 $16.83
Resistance Level N/A N/A
Average True Range (ATR) 2.17 0.35
MACD 0.03 0.14
Stochastic Oscillator 84.45 98.01

Price Performance

Historical Comparison
CNC
KVUE

About CNC Centene Corporation

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Share on Social Networks: